Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
37691
CAS Number:
866323-14-0
Belinostat
Purity:
≥ 98% (HPLC)
Synonym(s):
(E)-N-Hydroxy-3-[3-(N-phenylsulfamoyl)phenyl]acrylamide
Documents
$251.68 /25MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Belinostat is a potent histone deacetylase (HDAC) inhibitor, recognized for its significant role in cancer therapy, particularly in the treatment of peripheral T-cell lymphoma (PTCL). This compound functions by altering the expression of genes involved in cell cycle regulation and apoptosis, making it a valuable tool in oncology research and therapeutic applications. Belinostat's unique mechanism of action allows it to enhance the efficacy of other anticancer agents, providing a synergistic effect that can lead to improved patient outcomes.

In addition to its primary use in cancer treatment, Belinostat is being explored for its potential applications in various other therapeutic areas, including neurodegenerative diseases and inflammatory disorders. Its ability to modulate gene expression makes it a promising candidate for research into epigenetic therapies. Researchers and industry professionals can leverage Belinostat's properties to develop innovative treatment strategies and explore new avenues in drug development, making it an essential compound in the pharmaceutical landscape.

Synonyms
(E)-N-Hydroxy-3-[3-(N-phenylsulfamoyl)phenyl]acrylamide
CAS Number
866323-14-0
Purity
≥ 98% (HPLC)
Molecular Formula
C15H14N2O4S
Molecular Weight
318.35
MDL Number
MFCD08064035
PubChem ID
53437714
Melting Point
160 ?C (dec.)
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at 2 - 8 °C
General Information
Synonyms
(E)-N-Hydroxy-3-[3-(N-phenylsulfamoyl)phenyl]acrylamide
CAS Number
866323-14-0
Purity
≥ 98% (HPLC)
Molecular Formula
C15H14N2O4S
Molecular Weight
318.35
MDL Number
MFCD08064035
PubChem ID
53437714
Melting Point
160 ?C (dec.)
Appearance
White to light yellow to light orange powder to crystal
Conditions
Store at 2 - 8 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Belinostat is widely utilized in research focused on:

  • Cancer Treatment: Primarily used in oncology, Belinostat is an FDA-approved drug for treating peripheral T-cell lymphoma, providing a targeted approach to combat this aggressive cancer type.
  • Histone Deacetylase Inhibition: As a histone deacetylase (HDAC) inhibitor, it plays a crucial role in epigenetic regulation, making it valuable for studies on gene expression and cellular differentiation.
  • Combination Therapies: Researchers are exploring its effectiveness in combination with other cancer therapies, enhancing treatment efficacy and potentially reducing resistance in cancer cells.
  • Preclinical Studies: Belinostat is frequently used in laboratory settings to investigate its effects on various cancer cell lines, aiding in the development of new therapeutic strategies.
  • Potential in Other Diseases: Beyond cancer, ongoing research is examining its role in treating other conditions, such as autoimmune diseases, showcasing its versatility in therapeutic applications.

Citations